logo
The College Board Exposed: Nonprofit Or $1.6 Billion Testing Monopoly In Disguise?

The College Board Exposed: Nonprofit Or $1.6 Billion Testing Monopoly In Disguise?

Forbes26-05-2025
Students testing on computers
Founded 1900 to democratize college access, the College Board now straddles an uncomfortable line between its nonprofit mission and corporate-scale revenues. While technically structured as a member organization—with 6,000 high schools and colleges paying annual dues—its financial reality tells a different story.
The math reveals a stark imbalance. Since its inception, cumulative membership dues may total $1.5 billion when adjusted for inflation, but that pales next to the $10+ billion reaped from SATs and AP exams since 1990. This reliance on testing revenue has reshaped the organization's priorities, transforming it from a collaborative membership alliance into a de facto corporate entity with a testing monopoly.
Three strategies underpin the College Board's financial dominance. First, its testing empire operates like a well-oiled machine. The SAT suite—taken by 2 million students annually—generates $200–300 million from base fees and ancillary charges like $15 score reports. Meanwhile, the Advanced Placement (AP) program, which administered 5 million exams at $99 each in 2025, rakes in nearly $500 million, supplemented by millions from course materials and teacher training . Even middle schoolers are monetized through the PSAT 8/9, a controversial exam for 13-year-olds that locks schools into multi-year testing contracts.
Second, the organization has funneled $1.32 billion to Caribbean subsidiaries since 2011; a maneuver critics allege minimizes taxes on its approximately almost $2 billion in assets. Third, perhaps most ethically fraught, is its reliance on underpaid educators. Teachers grade AP exams for about $30/hour—less than half the rate of private tutors—similar to the honorarium paid to SAT proctors. Schools generally pay the cost of proctoring the PSAT. This labor model saves the College Board millions of dollars annually, often subsidizing profits through public school budgets.
Recent controversies highlight how financial incentives increasingly override educational goals. The 2025 digital SAT rollout was plagued by technical failures, the launch stranded students mid-test, with critics accusing the College Board of rushing to outpace its rival, the ACT . Technical issues with AP Classroom and this year's AP Psychology exam further erodes confidence. Its handling of the AP African American Studies curriculum sparked outrage when the organization diluted course content amid political pushback.
Even the pandemic failed to curb revenue-first thinking. Despite 1,900 colleges adopting test-optional policies post-COVID, the College Board lobbied aggressively to preserve SAT mandates. Such decisions align with CEO David Coleman's over $2.5 million compensation package—triple the average for nonprofit leaders—raising questions about whom the organization truly serves.
The Advanced Placement program embodies the College Board's contradictions. While studies show AP courses improve college readiness for underserved students, barriers persist. Exams cost $99 each—a burden for low-income districts—and recent recalibrating of test scores have sparked concerns about score inflation.
Moreover, schools often narrow curricula to align with AP frameworks, sidelining electives and critical thinking. AP's benefits are real but uneven. The program's success hinges on equitable access, yet the College Board profits from the very inequities it claims to address. The College Board does offer discounts for documented low income students, but the over $50 fee is still steep for low-income students.
The College Board's legacy is a study in contrasts. On one hand, AP courses correlate with higher college graduation rates, and standardized metrics help colleges evaluate applicants across diverse educational backgrounds. On the other, its products perpetuate systemic inequities. SAT scores, for instance, continue to be highly correlated with family income. At the same time, the PSAT 8/9 exemplifies profit-driven priorities, subjecting 13-year-olds to high-stakes testing with scant evidence of academic benefit.
Compounding these issues is the organization's labor exploitation. By outsourcing proctoring and grading to underpaid educators, the College Board extracts value from public schools while privatizing profits—a dynamic that mirrors gig economy practices more than educational stewardship.
The College Board must undergo a radical transformation to reclaim its nonprofit mission. Executive pay should align with nonprofit norms (under $500,000), not corporate benchmarks. Testing for students under 16 ought to be eliminated entirely, freeing schools from costly, developmentally inappropriate mandates. Proctoring and grading labor must be fairly compensated, and offshore financial dealings must be disclosed to the public.
Until these reforms materialize, the organization's 125-year legacy will remain shadowed by a question at the heart of its identity: Who benefits most—students or shareholders?
The College Board's nonprofit status hinges on a delicate balance—one increasingly tilted toward Wall Street, not classrooms. As education evolves, stakeholders must demand accountability from an organization that shapes millions of futures… and profits immensely from uncertainty.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Keybanc Hikes Spotify Technology S.A. (SPOT)'s Price Target To $860, Maintains Overweight Rating
Keybanc Hikes Spotify Technology S.A. (SPOT)'s Price Target To $860, Maintains Overweight Rating

Yahoo

timea minute ago

  • Yahoo

Keybanc Hikes Spotify Technology S.A. (SPOT)'s Price Target To $860, Maintains Overweight Rating

Spotify Technology S.A. (NYSE:SPOT) is among the 13 Best Global Stocks to Buy Right Now. On July 11, Keybanc lifted the stock's price target to $860 from $640, while maintaining an Overweight rating for its shares. The adjustment represents significant upside potential, given its share price of $674.46 at the close on July 23. Copyright: dennizn / 123RF Stock Photo The firm said that it expects Spotify Technology S.A. (NYSE:SPOT)'s second-quarter results and guidance for the third quarter to contain some variability related to foreign exchange, seasonal gross margin dynamics, and social charges. The analyst has advised investors to buy any near-term dips and reiterated that its core thesis remains intact. Keybanc believes that music is under-monetized in a price inflationary market with favorable competitive dynamics and several initiatives that support high-teens revenue growth. In other news, Deutsche Bank on Wednesday also raised Spotify Technology S.A. (NYSE:SPOT)'s target price to $775 from $700 and maintained a Buy rating for its shares. The Luxembourg-based company, which provides digital music-streaming services worldwide, has seen impressive returns in 2025, gaining 51% year-to-date. While we acknowledge the potential of SPOT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Small Cap Defense Stocks to Buy According to Hedge Funds and 13 Best Booming Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Maxwell is talking 'about everybody' in meetings with the deputy attorney general.
Maxwell is talking 'about everybody' in meetings with the deputy attorney general.

Yahoo

timea minute ago

  • Yahoo

Maxwell is talking 'about everybody' in meetings with the deputy attorney general.

Revelations could be near at hand in the Jeffrey Epstein saga as Ghislaine Maxwell has been granted limited immunity to speak freely in her meetings with Deputy Attorney General Todd Blanche. Blanche traveled to the Tallahassee, Florida, prison where the convicted accomplice of late sex offender Jeffrey Epstein is serving a 20-year sentence, for a nine-hour interview over two days. ABC News first reported on the limited immunity, meaning Maxwell can disclose information without criminally implicating herself. 'She answered questions about everybody,' attorney David Oscar Markus told reporters on Friday evening. The meetings were reportedly initiated by Maxwell herself.

Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment

Yahoo

timea minute ago

  • Yahoo

Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment

We recently compiled a list of Vertex Pharmaceuticals Incorporated stands second on our list and has recently launched the first non opioid acute pain treatment. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a global biotech firm based in Boston, is known for developing innovative treatments for serious diseases like cystic fibrosis, sickle cell disease, and beta thalassemia. The company is recognized for its strong pipeline targeting unmet medical needs. In July 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) launched JOURNAVX (suzetrigine), a first-in-class, non-opioid treatment for moderate-to-severe acute pain. JOURNAVX, an oral NaV1.8 pain signal inhibitor, was named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc. It represents the first new class of pain medicine in decades and offers a safer alternative to opioids by directly targeting pain pathways without addiction risks. This launch marks a major advancement in pain management, aligning with public health efforts to reduce opioid use. JOURNAVX is especially relevant for acute pain scenarios such as post-surgical recovery and injury care. A closeup of pills in a pharmacy, representing the high quality medications of the company. Beyond acute pain, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) continues to expand its reach. Its next-gen cystic fibrosis therapy, ALYFTREK, received approval from the European Commission in July 2025, strengthening its global leadership in this area. The company is also advancing gene-editing therapies like CASGEVY for sickle cell and beta thalassemia, and is developing treatments for kidney disease, type 1 diabetes, and rare genetic disorders. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store